Clinical trial
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis…
NCT02284568 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT02284568 |
|---|---|
| Title | A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo |
| Official title | A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS) |
| Acronym | ARPEGGIO |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Progressive Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Placebo, Laquinimod |
| Enrollment | 374 |
| Start date | Jan 12, 2015 |
| Primary completion | May 4, 2017 |
| Completion | Oct 1, 2017 |
| First posted | Nov 6, 2014 |
| Last update posted | Mar 10, 2022 |
| Countries | Canada, Germany, Italy, Netherlands, Poland, Russia, Spain, Ukraine, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: